港股異動 | 培力農本方漲13% 就疫情中醫藥保健品 反響良好
格隆匯2月17日丨培力農本方(1498.HK)盤中漲13.41%,報0.93港元,總市值3.67億港元。近日香港第五波疫情兇猛,醫療系統超負荷,中藥配方顆粒龍頭企業培力農本方就疫情大力推廣各類中藥保健品,且診所端推出抗疫療程藥包,市場反響良好。香港民建聯表示,近期香港出現中成藥搶購潮,顯示市民相信中醫對新冠肺炎的療效。香港註冊中醫學會表示,根據國家衞健委指引,現時國家已有針對輕、中、重症及恢復治療的"三藥三方",證實對治療新冠肺炎有良好、有效及安全性的效果,均適用於香港現時情況,相信將有助於香港抗擊疫情。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.